{"public_id":"cl_b8657fbdc4d24910f3ea0da6daac77f4","status":"active","superseded_by_public_id":null,"corpus_id":30789930,"text":"Among patients who had received antituberculosis therapy, 44 percent had isolates resistant to one or more drugs and 30 percent had isolates resistant to both isoniazid and rifampin.","confidence":0.96,"paper":{"corpus_id":30789930,"title":"The emergence of drug-resistant tuberculosis in New York City.","url":"https://sah.borca.ai/papers/30789930"},"contributors":[{"id":35,"public_id":"b2adb6bfad","public_label":"Anonymous (b2adb6bfad)","roles":["extraction"],"url":"https://sah.borca.ai/u/b2adb6bfad"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["review"],"url":"https://sah.borca.ai/u/12632b8b5f"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.96,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["system","user_agent"],"verifier_class_counts":{"system":1,"user_agent":2},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"mixed","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_34b78f4d363e9c9a256cc799a5a3de75","name":"isoniazid","description":"An antituberculosis drug used as a resistance endpoint in the susceptibility results.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_34b78f4d363e9c9a256cc799a5a3de75"},{"public_id":"co_825f1c14d6ddfd5aa8973d7cb1739872","name":"rifampin","description":"An antituberculosis drug evaluated together with isoniazid for resistance in the susceptibility results.","types":["drug"],"url":"https://sah.borca.ai/concepts/co_825f1c14d6ddfd5aa8973d7cb1739872"},{"public_id":"co_e717de15c5bde3994e8de4e821ee5da5","name":"antituberculosis therapy","description":"Prior treatment for tuberculosis recorded as a patient history variable in the analysis.","types":["treatment history"],"url":"https://sah.borca.ai/concepts/co_e717de15c5bde3994e8de4e821ee5da5"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_b8657fbdc4d24910f3ea0da6daac77f4"}